Results 41 to 50 of about 110,250 (249)

Soft Tissue Sarcomas

Annals of Surgery, 1975
One hundred fifty-five adult patients with "operable" soft part sarcomas including rhabdomyosarcoma, liposarcoma, leiomyosarcoma and fibrosarcoma of the trunk and extremities are reviewed. Local recurrences of 93% and 60% occurred after local and wide excisions of the primary tumor.
R E, Gerner, G E, Moore, J W, Pickren
openaire   +3 more sources

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model

Advanced Science, EarlyView.
FOS3D describes fluorescent (F) osteosarcoma (OS) cells in a tri‐dimensional (3D) model. The study comprises three phases: development, where biofabrication parameters are tuned to achieve cytocompatibility and tumor‐specific mechanical properties in cell‐laden gelatin methacryloyl constructs; validation, where whole‐well fluorescence reading is ...
William Humble, Wiktor Zywicki, Enrico Lucarelli, Ania Naila Guerrieri, Francesca Taraballi, Gianluca Cidonio, Claudia Di Bella, Carmine Onofrillo, Andrea J. O'Connor, Serena Duchi   +9 more
wiley   +1 more source

Trabectedin in Soft Tissue Sarcomas [PDF]

Marine Drugs, 2015
Soft tissue sarcomas are a group of rare tumors derived from mesenchymal tissue, accounting for about 1% of adult cancers. There are over 60 different histological subtypes, each with their own unique biological behavior and response to systemic therapy.
Bradley J. Petek, Elizabeth T. Loggers, Seth M. Pollack, Robin L. Jones   +3 more
openaire   +3 more sources

Nerve Growth Factor is Sufficient to Cause Multiple Osteoarthritis‐Relevant Pathologic Features in Naïve Murine Knee Joints

Arthritis &Rheumatology, EarlyView.
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects
Alia M. Obeidat, Michael D. Newton, Jun Li, Baofeng Hu, Shingo Ishihara, Lindsey Lammlin, Lucas M. Junginger, Easton C. Farrell, Lai Wang, Frank C. Ko, Richard J. Miller, Carla R. Scanzello, Tristan Maerz, Rachel E. Miller, Anne‐Marie Malfait   +14 more
wiley   +1 more source

Lymphadenectomy in the treatment of sarcomas – indications and technique

Oncology Reviews
Sarcomas are a rare type of malignancy with limited treatment options so far. This analysis aimed to describe the impact of lymphadenectomy on treating sarcoma patients. Sarcomas characterized by lymphatic spread are rare.
Piotr Dunaj, Piotr Dunaj, Ewa Żukowska, Ewa Żukowska, Anna M. Czarnecka, Maria Krotewicz, Aneta Borkowska, Paulina Chmiel, Paulina Chmiel, Tomasz Świtaj, Piotr Rutkowski   +10 more
doaj   +1 more source

Soft Tissue Sarcomas of the Kidney

Rare Tumors, 2015
Soft tissue sarcomas are rare mesenchymal tumors. Amongst others, primitive neuroectodermal tumors (PNET) of the kidney and synovial sarcoma of the kidney belong to the group of soft tissue sarcomas. Synovial sarcomas can occur almost anywhere in the body, most frequently, however, in the lower (62%) or upper extremities (21%).
Köhle O, Abt D, Rothermundt C, Öhlschlegel C, Brugnolaro C, Schmid HP   +5 more
openaire   +4 more sources

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma

Current Oncology
Mesenchymal chondrosarcoma (MCS) is characterised by small round cell biology, frequent HEY1-NCOA2 fusion, and high vascularity. These features plausibly lessen extracellular matrix barriers and confer relative chemosensitivity.
Piotr Remiszewski, Julia Wąż, Sławomir Falkowski, Piotr Rutkowski, Anna M. Czarnecka   +4 more
doaj   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source